Contents
SALES & MARKETING
30
The latest buzz in sales force effectiveness
How sales teams stand to gain from network
intelligence and new web-based detailing
approaches
R&D
33
Innervation or enervation in pharma?
Reports abound about pharma’s productivity crisis,
but is the industry really in such a bad way?
40
38
Stem cells continue to excite
Controversial and emotive, yet stem cell research
Introduction
All eyes on oncology
is still capturing the imagination of the R&D
community
5
Industry’s most explored therapy area
witnesses both high-profile successes and
Restructuring is the name
44
of the game in 2008
failures in 2008
Japanese approvals marked by high-need
Given current turmoil in the financial markets,
products
should we be worried about a failure in the
Initiatives aimed at bringing Japan’s therapeutic
pharmaceutical sector?
offerings more in line with other developed
markets begin to bear fruit
THE SCRIP 100
8
46
US NME approvals: cancer no longer
Pfizer clings to top spot
reigns supreme
The US giant continues to reign, but competition
Cancer and HIV therapies take a back seat to
among the other heavyweights hots up
constipation and hypertension in 2008
12
48
Life after M&A
EU drug approvals roundup
How two perfectly matched CROs merged to
Generics and biosimilars join innovative drugs in
form a global player
the queue of products going through the EU’s
centralised procedure
BUSINESS
15
50
The next challenge for big pharma’s
Mr Fix-it
Schering-Plough boss Fred Hassan mulls over the
18
Empowerment through IT
Pharma needs tools to track and report on clinical
data and the IT community is evolving to respond
to that
US election and outlines his personable approach
to doing business
M&A: activity continues DRUG DELIVERY
23
apace within pharma
53
Large buyouts capture the headlines while
Destination Moscow…
Deals define drug delivery space in 2008
numerous smaller-scale transactions target
Merck & Co’s head of global pharmaceuticals
Dealmaking continues apace in the drug delivery
Adam Schechter explains why he clocks up so
biologics, generics and the speciality space with
sector with players cashing in on new and
many air miles
the promise of business model diversification innovative technologies
25
2008 stock tracker: how robust is pharma?
Scrip 100 sponsor
Biopharmaceutical share prices held fast against
extreme market volatility in 2008, but who were
the winners and losers?
Sponsors
28
How to spend it
Pharma through the eyes of a global private
equity player
www.scripnews.com/supplements Scrip 100
3
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128